--- title: "USANA Health Sciences | 10-K: FY2027 Revenue Misses Estimate at USD 925.26 M" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/279310126.md" datetime: "2026-03-16T19:00:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279310126.md) - [en](https://longbridge.com/en/news/279310126.md) - [zh-HK](https://longbridge.com/zh-HK/news/279310126.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/279310126.md) | [English](https://longbridge.com/en/news/279310126.md) # USANA Health Sciences | 10-K: FY2027 Revenue Misses Estimate at USD 925.26 M Revenue: As of FY2027, the actual value is USD 925.26 M, missing the estimate of USD 1.001 B. EPS: As of FY2027, the actual value is USD 0.58, missing the estimate of USD 2.29. EBIT: As of FY2027, the actual value is USD 35.86 M. ### Overall Financial Performance - #### Net Sales In 2025, consolidated net sales for USANA Health Sciences, Inc. increased by 8.3% to $925.3 million, up from $854.5 million in 2024 . This growth was primarily driven by $130.0 million in incremental sales from Hiya, partially offset by a decline in the core nutritional segment . Unfavorable currency exchange rates decreased net sales by an estimated $3.1 million in 2025 . - #### Net Earnings Attributable to USANA Net earnings attributable to USANA Health Sciences, Inc. decreased by 74.4% to $10.8 million in 2025 compared to 2024, mainly due to a lower operating margin and a substantial increase in the effective tax rate . - #### Gross Profit Consolidated gross profit decreased by 280 basis points to 78.3% of net sales in 2025, down from 81.1% in 2024 . This decline is largely attributed to the inclusion of Hiya, which has lower gross margins . - #### Earnings from Operations Consolidated earnings from operations were $37,432 in 2025, compared to $66,324 in 2024 and $93,071 in 2023 . - #### Effective Tax Rate The effective tax rate increased to 72.4% of pre-tax earnings in 2025, up from 44.9% in 2024 . This was primarily due to lower U.S. earnings before taxes (including cost realignment and impairment) while foreign taxes remained relatively similar . - #### Cost Realignment and Impairment In 2025, USANA Health Sciences, Inc. incurred a one-time charge of $6,463 for cost realignment and recorded a non-cash goodwill impairment charge of $6,527 and a non-cash amortized intangible asset impairment charge of $440 . - #### R&D Expenses USANA Health Sciences, Inc. expended $10.7 million on product R&D activities in 2025, compared to $11.6 million in 2024 and $11.4 million in 2023 . ### Core Nutritional Segment - #### Segment Revenue Net sales in the core nutritional business (including the ‘other’ category) were $793.3 million in 2025, representing a 6.9% decrease from 2024 . On a constant currency basis, net sales declined by 6.6% . - #### Active Customers As of January 3, 2026, the core nutritional business had approximately 387,000 active Customers worldwide, a 14.8% decrease from 454,000 in December 2024 . This decrease in active Customers was partially offset by a 4.4% increase in average spend per customer . - #### Brand Partner Incentives Brand Partner incentives decreased by 30 basis points to 42.4% of segment net sales in 2025, compared with 42.7% in the prior year, mainly due to the ‘other’ category not incurring such expenses . Excluding the ‘other’ category, Brand Partner incentives expense increased by 5 basis points to 43.3% of core nutritional net sales . - #### Selling, General and Administrative Expenses For the core nutritional segment, these expenses increased by 150 basis points relative to net segment sales but decreased by $6.9 million in absolute terms compared to the prior year . - #### Geographic Performance (YoY local currency net sales, active customers, average spend) - **Asia Pacific**: Net sales declined 8.2% (-8.0% constant currency) . Active Customers declined 10.8%, with average spend per customer up 3.2% . - **China**: Local currency net sales -7.4%, Active Customers -10.9%, Average spend per active Customer 3.8% . - **South Korea**: Local currency net sales -5.8%, Active Customers -6.8%, Average spend per active Customer 1.7% . - **Malaysia**: Local currency net sales -16.7%, Active Customers -17.3%, Average spend per active Customer 1.2% . - **Australia**: Local currency net sales -12.4%, Active Customers -9.1%, Average spend per active Customer -3.8% . - **Americas and Europe**: Net sales declined 8.9% (-7.8% constant currency) . Active Customers declined 14.4%, with average spend per customer up 8.6% . - **United States**: Local currency net sales -7.8%, Active Customers -14.9%, Average spend per active Customer 8.3% . - **Canada**: Local currency net sales -4.3%, Active Customers -11.1%, Average spend per active Customer 7.6% . - **Mexico**: Local currency net sales -8.3%, Active Customers -16.9%, Average spend per active Customer 10.1% . ### Hiya Direct-to-Consumer Segment - #### Segment Revenue Hiya’s net sales were $131,971 in 2025, a significant increase from $1,970 in 2024, as 2025 represented a full year of operations post-acquisition . - #### Active Monthly Subscribers As of January 3, 2026, Hiya had approximately 181,700 active Monthly Subscribers . - #### Gross Profit Hiya carries lower gross margins relative to the core nutritional segment . - #### Selling, General and Administrative Expenses This segment has a higher mix of selling, general and administrative expenses, mainly concentrated in advertising spend, payroll, other professional services, and amortization of acquired intangible assets . ### Other Category (Rise and Oola) - \#### Segment RevenueNet sales for the ‘Other’ category were $17,834 in 2025, a 164.4% increase from $6,744 in 2024 . ### Cash Flow - #### Cash and Cash Equivalents Cash and cash equivalents decreased to $158.4 million at January 3, 2026, from $181.8 million at December 28, 2024 . - #### Operating Cash Flow Net cash flow provided by operating activities totaled $22.3 million in 2025, compared to $61.0 million in 2024 and $70.6 million in 2023 . - #### Investing Activities Cash used in investing activities was $10.1 million in 2025, primarily for property and equipment purchases . - #### Financing Activities Cash used in financing activities was $40.6 million in 2025, including $27.5 million for common stock repurchases . - #### Restricted Cash Restricted cash included in other assets was $2,860 as of January 3, 2026, and $2,740 as of December 28, 2024 . ### Outlook / Guidance USANA Health Sciences, Inc. plans to continue investing in R&D to advance expertise in cellular nutrition and overall health and wellness, with further investment into early-stage research and scientific innovation in 2026 . The company also intends to accelerate technology initiatives to modernize core systems, improve customer experience, and create future cost efficiencies across its IT infrastructure . Additionally, 优莎娜 expects to continue pursuing acquisition opportunities in the health and wellness space that strengthen, diversify, and grow its worldwide business . ### 相關股票 - [USANA Health Sciences (USNA.US)](https://longbridge.com/zh-HK/quote/USNA.US.md) ## 相關資訊與研究 - [USANA CEO Kevin Guest Calls for Daily Health Routines on World Health Day | USNA Stock News](https://longbridge.com/zh-HK/news/281353855.md) - [USANA Health Sciences (NYSE:USNA) Releases FY 2026 Earnings Guidance](https://longbridge.com/zh-HK/news/277617844.md) - [QIND Reports FY 2025 Results: 45.9% Revenue Growth, Core Turnaround Action Highlights | QIND Stock News](https://longbridge.com/zh-HK/news/281375930.md) - [Scinai Immunotherapeutics reports FY results](https://longbridge.com/zh-HK/news/281477360.md) - [Sri Lotus Developers Grants 1.2 Million ESOPs Under 2024 Scheme](https://longbridge.com/zh-HK/news/281348606.md)